COVID-19 Vaccine Efficacy in Participants With Weakened Immune Systems From 4 Randomized Controlled Trials
Sherman A, Tuan J, Cantos V, Adeyiga O, Mahoney S, Ortega-Villa A, Tillman A, Whitaker J, Davis A, Leav B, Hirsch I, Sadoff J, Dunkle L, Gilbert P, Janes H, Kublin J, Goepfert P, Kotloff K, Rouphael N, Falsey A, Sahly H, Sobieszczyk M, Huang Y, Neuzil K, Corey L, Grinsztejn B, Gray G, Nason M, Baden L, Gay C. COVID-19 Vaccine Efficacy in Participants With Weakened Immune Systems From 4 Randomized Controlled Trials. Clinical Infectious Diseases 2024, 79: 364-374. PMID: 38598658, PMCID: PMC11327800, DOI: 10.1093/cid/ciae192.Peer-Reviewed Original ResearchSevere COVID-19Vaccine efficacyImmune systemBlinded phaseWell-controlled HIVPhase 3 trialSARS-CoV-2 vaccinesSevere COVID-19 casesWeakened immune systemRandomized-controlled trialsCOVID-19 vaccine efficacyRandomized controlled trialsPlacebo-controlledCross-protocol analysisImmunocompromised conditionsRandomized controlled efficacy trialPrimary seriesMedical historySymptomatic endpointsSevere diseaseConsensus panelEfficacy trialsSARS-CoV-2Nutritional disordersGeneral population